38.08
前日終値:
$38.74
開ける:
$38.28
24時間の取引高:
1.21M
Relative Volume:
1.37
時価総額:
$3.01B
収益:
$399.58M
当期純損益:
$-54.04M
株価収益率:
-50.77
EPS:
-0.75
ネットキャッシュフロー:
$40.13M
1週間 パフォーマンス:
-9.91%
1か月 パフォーマンス:
-9.93%
6か月 パフォーマンス:
+58.87%
1年 パフォーマンス:
-17.47%
Veracyte Inc Stock (VCYT) Company Profile
名前
Veracyte Inc
セクター
電話
(650) 243-6300
住所
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
VCYT
Veracyte Inc
|
38.08 | 3.06B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Morgan Stanley | Underweight |
| 2025-10-20 | 開始されました | Canaccord Genuity | Hold |
| 2025-03-20 | 開始されました | Craig Hallum | Buy |
| 2024-12-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-16 | 開始されました | UBS | Buy |
| 2024-10-10 | 開始されました | Guggenheim | Buy |
| 2024-02-23 | 繰り返されました | Needham | Buy |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-11-18 | 再開されました | Goldman | Buy |
| 2021-06-15 | 開始されました | Raymond James | Outperform |
| 2021-02-18 | 再開されました | Needham | Buy |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2019-07-31 | 開始されました | Lake Street | Buy |
| 2019-07-02 | 開始されました | Needham | Buy |
| 2018-11-29 | ダウングレード | Janney | Buy → Neutral |
| 2018-10-31 | アップグレード | Janney | Neutral → Buy |
| 2017-11-07 | ダウングレード | Janney | Buy → Neutral |
| 2017-11-07 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 再開されました | BTIG Research | Buy |
| 2016-11-14 | 再開されました | Leerink Partners | Outperform |
| 2015-12-18 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-11 | 繰り返されました | Leerink Partners | Outperform |
| 2013-11-26 | 開始されました | William Blair | Outperform |
すべてを表示
Veracyte Inc (VCYT) 最新ニュース
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now - Finviz
Can Veracyte Inc. ride the EV waveQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Earnings Miss: Can Veracyte Inc expand into new marketsEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Veracyte, Inc. (VCYT) Stock Analysis: A Diagnostic Leader With 17.49% Potential Upside - DirectorsTalk Interviews
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating - MSN
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again - primepublishers.com
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate - Chartmill
Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT) - simplywall.st
Swing Trade: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantJuly 2025 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio - Sahm
Is Veracyte’s (VCYT) Confident Double‑Digit Revenue Outlook Altering The Investment Case For Investors? - Yahoo Finance
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating - Finviz
Centene Expands Palliative Care Access in Ohio Through Tuesday Health - Nasdaq
QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. $VCYT - MarketBeat
S P Trends: Is Veracyte Inc showing insider buyingTrade Entry Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
State of Alaska Department of Revenue Takes $1.50 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Trade Recap: Is Veracyte Inc stock a value trapJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 165,094 Shares of Veracyte, Inc. $VCYT - MarketBeat
SG Americas Securities LLC Increases Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (NASDAQ:VCYT) Cut to Hold at Zacks Research - MarketBeat
Is Veracyte’s 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte (VCYT)? - Sahm
Louisiana State Employees Retirement System Invests $1.24 Million in Veracyte, Inc. $VCYT - MarketBeat
Lung Cancer Diagnostics Market Size and Forecast 2025–2033 - Vocal
Breakout Move: What is the dividend yield of CMMBJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Volume Recap: Is Veracyte Inc. stock a top pick in earnings seasonStock Surge & Accurate Trade Setup Notifications - Bộ Nội Vụ
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $44 - 富途牛牛
Morgan Stanley initiates coverage of Veracyte, Inc. (VCYT) - MSN
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook - Investing.com Australia
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook By Investing.com - Investing.com India
Needham reiterates Buy rating on Veracyte stock after strong Q4 preannouncement - Investing.com Nigeria
Summit Creek Advisors LLC Makes New $8.52 Million Investment in Veracyte, Inc. $VCYT - MarketBeat
Veracyte stock outlook positive as Leerink reiterates Outperform rating By Investing.com - Investing.com South Africa
Veracyte stock outlook positive as Leerink reiterates Outperform rating - Investing.com India
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results - 01net
Veracyte (VCYT) Sets Ambitious Revenue Growth Targets for 2026 - GuruFocus
Veracyte (VCYT) Poised for Growth with New Product Launches in 2 - GuruFocus
BRIEF-Veracyte Outlook FY Revenue Growth 16% - TradingView — Track All Markets
Published on: 2026-01-11 01:59:58 - ulpravda.ru
Veracyte Reports Strong Q3 2025 Financial Performance - MSN
Market Wrap: Can Veracyte Inc 12V stock reach 200 price targetJuly 2025 Final Week & Precise Buy Zone Identification - Bộ Nội Vụ
Can Veracyte Inc. (12V) stock reach $200 price targetJuly 2025 Weekly Recap & AI Driven Price Predictions - Улправда
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Veracyte Inc. stock could outperform in 2025July 2025 Decliners & Low Risk Growth Stock Ideas - Улправда
Veracyte Inc (VCYT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):